/RDNT
RDNT Stock - RadNet, Inc.
Healthcare|Medical - Diagnostics & ResearchNASDAQ
$76.68+7.39%
+$5.28 (+7.39%) • Dec 19
73
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.BUY
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.75
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).91
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.61
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+20.6%upside
Target: $92.48
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for RDNT
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$75.91 – $77.45
TARGET (TP)$92.50
STOP LOSS$70.55
RISK/REWARD1:2.6
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta1.49
52W High$85.84
52W Low$45.00
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $1.83B | $1.62B | $1.43B | $1.32B | $1.07B |
| Gross Profit | $249.12M | $221.39M | $165.72M | $191.80M | $105.94M |
| Gross Margin | 13.6% | 13.7% | 11.6% | 14.6% | 9.9% |
| Operating Income | $104.62M | $98.70M | $46.36M | $82.55M | $35.68M |
| Net Income | $2.79M | $3.04M | $10.65M | $24.73M | $-14,840,000 |
| Net Margin | 0.2% | 0.2% | 0.7% | 1.9% | -1.4% |
| EPS | $0.04 | $0.05 | $0.19 | $0.47 | $-0.29 |
Company Overview
RadNet, Inc., together with its subsidiaries, provides outpatient diagnostic imaging services in the United States. Its services include magnetic resonance imaging, computed tomography, positron emission tomography, nuclear medicine, mammography, ultrasound, diagnostic radiology, fluoroscopy, and other related procedures, as well as multi-modality imaging services. The company also develops and sells computerized systems for the diagnostic imaging industry, including picture archiving communications systems and related services; and develops and deploys AI suites to enhance radiologist interpretation of images in the field of mammography, as well as AI solutions for lung and prostate cancer. As of December 31, 2021, it owned and managed 347 centers in Arizona, California, Delaware, Florida, Maryland, New Jersey, and New York. The company was founded in 1981 and is headquartered in Los Angeles, California.
Visit WebsiteRating Distribution
Strong Buy
1
17%
Buy / Outperform
4
67%
Hold / Neutral
1
17%
Sell / Underperform
0%
Analyst Consensus🟢 Bullish
5 Bullish1 Neutral/Bearish
Price Targets
$52
Average Target
↓ 32.7% Downside
Now
$30
Low
$52
Average
$79
High
Based on 7 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| June 13th 2025 | B. Riley Securities | Initiation | Buy | $69 |
| March 5th 2025 | Raymond James | Upgrade | Strong Buy | $65← $85 |
| September 6th 2024 | Barclays | Upgrade | Overweight | $79← $57 |
| March 6th 2024 | Barclays | Initiation | Equal Weight | $48 |
| August 31st 2023 | Truist | Initiation | Buy | $40 |
| March 31st 2023 | CJS Securities | Initiation | Market Outperform | $30 |
| March 3rd 2023 | Raymond James | Upgrade | Outperform | $30 |
Earnings History & Surprises
RDNTBeat Rate
56%
Last 18 quarters
Avg Surprise
-210.1%
EPS vs Estimate
Beats / Misses
10/7
1 met exactly
Latest EPS
$0.20
Q4 2025
EPS Surprise History
Q1 24
+81.8%
$0.20vs$0.11
Q2 24
+177.8%
$0.07vs$-0.09
Q3 24
0.0%
$0.16vs$0.16
Q4 24
+32.5%
$0.18vs$0.14
Q1 25
+4.8%
$0.22vs$0.21
Q2 25
-105.9%
$-0.35vs$-0.17
Q3 25
+82.4%
$0.31vs$0.17
Q4 25
-10.3%
$0.20vs$0.22
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 7, 2026 | — | — | — | — |
Q1 2026 | Feb 26, 2026 | $0.19 | — | — | — |
Q4 2025 | Nov 9, 2025 | $0.22 | $0.20 | -10.3% | ✗ MISS |
Q3 2025 | Aug 10, 2025 | $0.17 | $0.31 | +82.4% | ✓ BEAT |
Q2 2025 | May 11, 2025 | $-0.17 | $-0.35 | -105.9% | ✗ MISS |
Q1 2025 | Feb 27, 2025 | $0.21 | $0.22 | +4.8% | ✓ BEAT |
Q4 2024 | Nov 10, 2024 | $0.14 | $0.18 | +32.5% | ✓ BEAT |
Q3 2024 | Aug 7, 2024 | $0.16 | $0.16 | 0.0% | = MET |
Q2 2024 | May 8, 2024 | $-0.09 | $0.07 | +177.8% | ✓ BEAT |
Q1 2024 | Feb 29, 2024 | $0.11 | $0.20 | +81.8% | ✓ BEAT |
Q4 2023 | Nov 8, 2023 | $0.06 | $0.14 | +133.3% | ✓ BEAT |
Q3 2023 | Aug 8, 2023 | $0.07 | $0.24 | +242.9% | ✓ BEAT |
Q2 2023 | May 9, 2023 | $-0.07 | $-0.08 | -14.3% | ✗ MISS |
Q1 2023 | Feb 28, 2023 | $0.15 | $0.11 | -26.7% | ✗ MISS |
Q4 2022 | Nov 9, 2022 | $0.16 | $0.09 | -43.8% | ✗ MISS |
Q3 2022 | Aug 9, 2022 | $0.05 | $0.15 | +200.0% | ✓ BEAT |
Q2 2022 | May 9, 2022 | $-0.00 | $-0.15 | -4602.2% | ✗ MISS |
Q1 2022 | Mar 1, 2022 | $0.19 | $0.13 | -31.6% | ✗ MISS |
Q4 2021 | Nov 8, 2021 | $0.20 | $0.21 | +5.0% | ✓ BEAT |
Q3 2021 | Aug 9, 2021 | $0.14 | $0.27 | +92.9% | ✓ BEAT |
Latest News
RadNet shares are trading lower after Hunterbrook Capital announced a short position.
📉 NegativeBenzinga•Dec 16, 2025, 02:23 PM
Watching RadNet; Hunterbrook Media Issues Report On Co Stating Hunterbrook Capital Is Short
📉 NegativeBenzinga•Dec 16, 2025, 02:22 PM
RadNet Files For Mixed Shelf Offering, Size Not Disclosed
➖ NeutralBenzinga•Dec 4, 2025, 10:08 PM
B. Riley Securities Maintains Buy on RadNet, Raises Price Target to $87
📈 PositiveBenzinga•Dec 1, 2025, 03:13 PM
RadNet's DeepHealth Unveils AI Powered Breast Suite Enhancing Detection Accuracy And Diagnostic Efficiency
📈 PositiveBenzinga•Dec 1, 2025, 11:07 AM
Reported Sunday, DeepHealth Launches DeepHealth OS And Enterprise Imaging AI Solutions At RSNA 2025 To Orchestrate End To End Imaging Experience
📈 PositiveBenzinga•Dec 1, 2025, 07:15 AM
Radnet's Deephealth Signs Wichita Radiological Group As First Customer For Its AI-Powered Operations Suite
📈 PositiveBenzinga•Nov 20, 2025, 11:04 AM
RadNet Data From Analysis Of AI-Driven Breast Cancer Screening Demonstrates Clinical Effectiveness, Benefit Of DeepHealth's AI Technology Across 579K Women
📈 PositiveBenzinga•Nov 17, 2025, 09:07 PM
Barclays Maintains Overweight on RadNet, Raises Price Target to $86
📈 PositiveBenzinga•Nov 13, 2025, 08:31 PM•Also:
Truist Securities Maintains Buy on RadNet, Raises Price Target to $90
📈 PositiveBenzinga•Nov 12, 2025, 06:13 PM
RadNet Acquires CIMAR UK, And Will Be Integrated Into RadNet's DeepHealth, Deal Terms Were Not Disclosed
📈 PositiveBenzinga•Nov 11, 2025, 11:07 AM
RadNet Raises FY2025 Sales Guidance from $1.930B-$1.990B to $1.985B-$2.025B vs $1.973B Est
📈 PositiveBenzinga•Nov 10, 2025, 01:41 PM
RadNet Q3 Adj. EPS $0.20 Misses $0.22 Estimate, Sales $522.869M Beat $494.413M Estimate
➖ NeutralBenzinga•Nov 10, 2025, 08:18 AM
RadNet Acquires Assets Of Alpha RT; Terms Not Disclosed
📈 PositiveBenzinga•Nov 5, 2025, 11:12 AM
Barclays Maintains Overweight on RadNet, Raises Price Target to $79
📈 PositiveBenzinga•Sep 3, 2025, 02:20 PM•Also:
Truist Securities Maintains Buy on RadNet, Raises Price Target to $81
📈 PositiveBenzinga•Sep 3, 2025, 12:39 PM
RadNet Reports Record Q2 Revenue
📈 PositiveThe Motley Fool•Aug 11, 2025, 05:46 PM
RadNet Posts Record Q2 Revenue Up 8%
📈 PositiveThe Motley Fool•Aug 11, 2025, 10:27 AM
Key deals this week: Qualcomm, Chart Industries, RadNet, AMD and more
📈 PositiveSeeking Alpha•Jun 7, 2025, 07:15 PM•Also: , ,
RadNet to acquire iCAD; iCAD shares jump more than 70%
📈 PositiveSeeking Alpha•Apr 15, 2025, 08:21 PM
Frequently Asked Questions about RDNT
What is RDNT's current stock price?
RadNet, Inc. (RDNT) is currently trading at $76.68 per share. The stock has moved +7.39% today.
What is the analyst price target for RDNT?
The average analyst price target for RDNT is $92.50, based on 1 analyst.
What sector is RadNet, Inc. in?
RadNet, Inc. operates in the Healthcare sector, specifically within the Medical - Diagnostics & Research industry. The company is traded on the NASDAQ exchange.
What is RDNT's market cap?
RadNet, Inc. has a market capitalization of $5.92 billion, making it a mid-cap company.
Does RDNT pay dividends?
No, RadNet, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorBLCO
Bausch + Lomb Corporation
$16.98
Mkt Cap: $6.0B
BRKR
Bruker Corporation
$46.48
Mkt Cap: $7.1B
BTSG
BrightSpring Health Services, Inc. Common Stock
$37.49
Mkt Cap: $6.8B
CHE
Chemed Corporation
$435.33
Mkt Cap: $6.4B
IRTC
iRhythm Technologies, Inc.
$174.17
Mkt Cap: $5.6B
KRYS
Krystal Biotech, Inc.
$240.80
Mkt Cap: $7.0B
MMSI
Merit Medical Systems, Inc.
$87.70
Mkt Cap: $5.2B
MTSR
Metsera, Inc.
$70.50
Mkt Cap: $7.4B
SHC
Sotera Health Company
$17.17
Mkt Cap: $4.9B
TFX
Teleflex Incorporated
$121.89
Mkt Cap: $5.4B
Explore stocks similar to RDNT for comparison